QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-astria-therapeutics-maintains-22-price-target

Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.

 oppenheimer-maintains-outperform-on-astria-therapeutics-raises-price-target-to-26

Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target f...

 hc-wainwright--co-reiterates-buy-on-astria-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $16 p...

 astria-therapeutics-q2-2024-adj-eps-043-misses-039-estimate

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of...

 td-cowen-initiates-coverage-on-astria-therapeutics-with-buy-rating-announces-price-target-of-35

TD Cowen analyst Stacy Ku initiates coverage on Astria Therapeutics (NASDAQ:ATXS) with a Buy rating and announces Price Targ...

 oppenheimer-maintains-outperform-on-astria-therapeutics-lowers-price-target-to-25

Oppenheimer analyst Hartaj Singh maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and lowers the price target f...

 hc-wainwright--co-reiterates-buy-on-astria-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $16 p...

 wedbush-reiterates-outperform-on-astria-therapeutics-maintains-22-price-target

Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $22 price target.

 astria-therapeutics-q1-2024-gaap-eps-038-inline

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate.

 hc-wainwright--co-maintains-buy-on-astria-therapeutics-lowers-price-target-to-16

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and lowers the price...

 wedbush-maintains-outperform-on-astria-therapeutics-raises-price-target-to-22

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-astria-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $18 pr...

 astria-therapeutics-announces-initial-proof-of-concept-results-from-the-alpha-star-phase-1b2-trial-of-star-0215-for-hae

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic...

 why-lifecore-biomedical-shares-are-trading-lower-by-around-32-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it con...

 hc-wainwright--co-reiterates-buy-on-astria-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $18 p...

 wedbush-reiterates-outperform-on-astria-therapeutics-maintains-17-price-target

Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $17 price target.

 hc-wainwright--co-reiterates-buy-on-astria-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $18 p...

 astria-therapeutics-q4-eps-086-down-from-072-yoy

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.86) per share. This is a 19.44 percent decrease over losses ...

 wedbush-reiterates-outperform-on-astria-therapeutics-maintains-17-price-target

Wedbush analyst Laura Chico reiterates Astria Therapeutics (NASDAQ:ATXS) with a Outperform and maintains $17 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION